 Mark Althoff
Concepts (58)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cells | 3 | 2026 | 435 | 0.810 |
Why?
| | Tumor Suppressor Proteins | 1 | 2020 | 321 | 0.540 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 425 | 0.520 |
Why?
| | Aminopeptidases | 1 | 2014 | 20 | 0.410 |
Why?
| | Membrane Proteins | 1 | 2020 | 1164 | 0.410 |
Why?
| | Cell Differentiation | 1 | 2020 | 2046 | 0.370 |
Why?
| | Transcription Factors | 1 | 2020 | 1734 | 0.360 |
Why?
| | Neoplastic Stem Cells | 2 | 2025 | 409 | 0.320 |
Why?
| | Caenorhabditis elegans | 1 | 2014 | 326 | 0.320 |
Why?
| | Mitochondria | 2 | 2024 | 992 | 0.230 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 2 | 2025 | 280 | 0.230 |
Why?
| | Niacinamide | 1 | 2026 | 104 | 0.230 |
Why?
| | Myelodysplastic Syndromes | 1 | 2026 | 165 | 0.210 |
Why?
| | Sulfonamides | 2 | 2025 | 583 | 0.200 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2025 | 127 | 0.200 |
Why?
| | cdc42 GTP-Binding Protein | 1 | 2020 | 21 | 0.160 |
Why?
| | Connexin 43 | 1 | 2020 | 36 | 0.160 |
Why?
| | Cell Self Renewal | 1 | 2020 | 52 | 0.160 |
Why?
| | Bone Marrow | 1 | 2020 | 306 | 0.140 |
Why?
| | Regeneration | 1 | 2020 | 197 | 0.140 |
Why?
| | Calcium | 1 | 2024 | 1190 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 981 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 686 | 0.130 |
Why?
| | Antigens, CD34 | 1 | 2016 | 89 | 0.120 |
Why?
| | Translocation, Genetic | 1 | 2016 | 119 | 0.120 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 72 | 0.120 |
Why?
| | Retinoids | 1 | 2015 | 33 | 0.110 |
Why?
| | Ikaros Transcription Factor | 1 | 2015 | 23 | 0.110 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 89 | 0.110 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2015 | 68 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 1963 | 0.110 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 141 | 0.110 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2016 | 337 | 0.100 |
Why?
| | Cell Proliferation | 1 | 2020 | 2507 | 0.090 |
Why?
| | Cells, Cultured | 1 | 2020 | 4148 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2025 | 881 | 0.090 |
Why?
| | Fertility | 1 | 2014 | 173 | 0.090 |
Why?
| | Reproduction | 1 | 2014 | 208 | 0.090 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 297 | 0.090 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 2129 | 0.080 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2883 | 0.070 |
Why?
| | Biomarkers | 1 | 2020 | 4295 | 0.070 |
Why?
| | Animals | 6 | 2025 | 38030 | 0.060 |
Why?
| | Signal Transduction | 1 | 2020 | 5216 | 0.060 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2026 | 26 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3542 | 0.060 |
Why?
| | Mice | 5 | 2025 | 18329 | 0.060 |
Why?
| | Blast Crisis | 1 | 2025 | 34 | 0.050 |
Why?
| | Mutation | 1 | 2015 | 4075 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2024 | 209 | 0.050 |
Why?
| | Humans | 7 | 2026 | 145475 | 0.040 |
Why?
| | Cytokines | 1 | 2026 | 2067 | 0.030 |
Why?
| | Receptors, Retinoic Acid | 1 | 2015 | 42 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2015 | 97 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2016 | 212 | 0.030 |
Why?
| | Cell Lineage | 1 | 2016 | 377 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2214 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4560 | 0.010 |
Why?
|
|
Althoff's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|